Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age of newborn through 17 years at time of enrollment~* At least 1 skin graft recipient site measuring at least 1% of total body surface area (TBSA)~* Total initial burn wounds estimated to measure less than 40% of TBSA~* Bleeding indicating treatment with rThrombin during the surgical procedure~* Females of child-bearing potential must have a negative urine or serum pregnancy test within 2 days prior to study-drug treatment~* informed consent document signed by legal representative (guardian) and approved by an institutional review board/independent ethics committee (IRB/IEC)~* Participant has signed an IRB/IEC-approved pediatric assent document, if applicable~Exclusion Criteria:~* Gestational age younger than 36 weeks at birth (for infants younger than 2 years)~* Documented active infection at the graft recipient site (participants with resolved infections at potential graft recipient sites are not excluded)~* Acute inhalation injury, as defined by bronchoscopic evidence of lower airway injury~* Currently undergoing autologous skin grafting for ischemic ulcer disease or cutaneous malignancies~* Presence of antibodies or hypersensitivity to the study drug or any of its components, other thrombin preparations, or coagulation factors~* Transfusion of whole blood, fresh frozen plasma, cryoprecipitate, or platelets within 24 hours prior to study-drug treatment (packed red blood cell transfusions are allowed)~* History of HIV infection or other immunodeficiency syndrome or is taking immunosuppressive or antirejection medications~* Medical, social, or psychosocial factors that, in the opinion of the investigator, could affect safety or compliance with study procedures~* Breastfeeding or being breastfed~* Treatment with any experimental agent within 30 days of study enrollment or treatment

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Recombinant thrombin (rThrombin), 1000 IU/mL (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).